ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Conformational variation of an extreme drug resistant mutant of HIV protease.
 PMID: 26397743       2015       Journal of molecular graphics & modelling
Method: Plasmid DNA encoding PR (subtype B of group M) with 20 mutations Q7K; L10F; I13V; I15V; D30N; V32I; L33F; E35D; M36I; S37N; I47V; I54L; Q58E; I62V; L63P; A71V; I84V; N88D; L89T and L90M (termed PR20) cloned between the Nde1 and BamH1 sites


  HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.
 PMID: 26558396       2015       PloS one
Table: N88D


  Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
 PMID: 26695135       2015       BMC bioinformatics
Introduction: L23I, D30N, E35G, M46I/L/V, G48V, I54L, G73S/T/C/A, T74S, V82A/F/S/T, I84V, N88D/S and L90M are other mutations correlated to NFV resistance.


  HIV-1 subtype characteristics of infected persons living in southwestern Greece.
 PMID: 26715861       2015       HIV/AIDS (Auckland, N.Z.)
Result: The 22 cases experiencing virologic failure presented with the following DRMs: M46I, F53LY, I54LTV, G73ST, L76V, V82AT, I84V, I185V, N88D, and L90M for PIs; L100I, K103NS, V179F Y181C, G190AS, V106A, K103N, and P225H for NNRTIs; and


  HIV-1 protease-substrate coevolution in nelfinavir resistance.
 PMID: 24719428       2014       Journal of virology
Abstract: In this study, we investigated the structural basis of coevolution at the Gag p1-p6 cleavage site with the nelfinavir (NFV) resistance D30N/N88D protease mutations.
Abstract: In this study, we investigated the structural basis of coevolution of the p1-p6 cleavage site with the nelfinavir (NFV) resistance D30N/N88D protease mutations by determining crystal structures of wild-type and NFV-resistant HIV-1 protease in complex with p1-p6 substrate peptide variants with L449F and/or S451N.


  High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.
 PMID: 24816790       2014       PloS one
Result: Reduced susceptibility to NFV/r in the remaining patient was caused by N88D.


  Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease.
 PMID: 23298236       2013       Journal of medicinal chemistry
Result: Similar changes in interactions of residues 30 and 88 have been reported in mutants containing D30N and N88D and also proposed to effect inhibition.
Discussion: Considering the positive association of mutation D30N and N88D, it would be interesting to study how N88D influences the structure of D30N in complex with this new inhibitor 1.


  Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
 PMID: 23590295       2013       Journal of medicinal chemistry
Introduction: Recently, we characterized a clinically derived HIV-1 protease (PR20) bearing 20 mutations [Q7K, L10F, I13V, I15V, D30N, V32I, L33F, E35D, M36I, S37N, I47V, I54L, Q58E, I62V, L63P, A71V, I84V, N88D, L89T and L90M] and extremely resist


  Transmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapy.
 PMID: 23469241       2013       PloS one
Table: N88D


  Sequence variability in p6 gag protein and gag/pol coevolution in human immunodeficiency type 1 subtype F genomes.
 PMID: 23458243       2013       AIDS research and human retroviruses
Abstract: Also, in our dataset of subtype F genomes a strong association between mutation P5L in the p1/p6 cleavage region of gag and the nelfinavir (NFV) resistance mutation N88D(PR) was found with no impact on the preference for any of the NFV resistance pathways.



Browser Board

 Co-occurred Entities




   Filtrator